Multidrug-Resistant Aspergillus fumigatus Carrying Mutations Linked to Environmental Fungicide Exposure — Three States, 2010–2017
Supporting Files
Public Domain
-
Sep 28 2018
-
Details
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR)
-
Personal Author:
-
Description:The environmental mold Aspergillus fumigatus is the primary cause of invasive aspergillosis. In patients with high-risk conditions, including stem cell and organ transplant recipients, Mortality exceeds 50%. Triazole antifungals have greatly improved survival (1); however, triazole-resistant A. fumigatus infections are increasingly reported Worldwide and are associated with increased treatment failure and Mortality (2). Of particular concern are resistant A. fumigatus isolates carrying either TR|/L98H or TR|/Y121F/T289A genetic resistance markers, which have been associated with environmental triazole fungicide use rather than previous patient exposure to antifungals (3,4). Reports of these triazole-resistant A. fumigatus strains have become common in Europe (2,3), but U.S. reports are limited (5). Because of the risk posed to immunocompromised patients, understanding the prevalence of such isolates in patients is important to guide clinical and public health decision-making. In 2011, CDC initiated passive laboratory monitoring for U.S. triazole-resistant A. fumigatus isolates through outreach to clinical laboratories. This system identified five TR|/L98H isolates collected from 2016 to 2017 (6), in addition to two other U.S. isolates collected in 2010 and 2014 and reported in 2015 (5). Four of these seven isolates were reported from Pennsylvania, two from Virginia, and one from California. Three isolates were collected from patients with invasive pulmonary aspergillosis, and four patients had no known previous triazole exposure. A. fumigatus resistant to all triazole medications is emerging in the United States, and clinicians and public health personnel need to be aware that resistant infections are possible even in patients not previously exposed to these medications.
-
Subjects:
-
Source:MMWR Morbidity Mortal Weekly Rep. 67(38):1064-1067.
-
Series:
-
DOI:
-
ISSN:0149-2195 (print) ; 1545-861X (digital)
-
Pubmed ID:30260939
-
Pubmed Central ID:PMC6188124
-
Document Type:
-
Place as Subject:
-
Pages in Document:4 pdf pages
-
Volume:67
-
Issue:38
-
Collection(s):
-
Main Document Checksum:urn:sha-512:57d601b737fed16bbc0d0a20a3e795249d9ebe6f6e8f66dcd0f53d153c7f40bb45c69b425c9ce950884184195f13dba2a2f67f5529127debd87939fbbf5a9d7f
-
Download URL:
-
File Type:
Supporting Files
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like
COLLECTION
Morbidity and Mortality Weekly Report (MMWR)